- What changed in OBX news today?
- Obsidian Therapeutics says Amsoki-Cel NSCLC phase 1 data expected in first half of 2027: Obsidian Therapeutics said Amsoki-Cel had a 67% overall response rate at the recommended phase 2 dose, with two complete and eight partial responses. The company expects NSCLC phase 1 data in the first half of 2027.
- Does Rallies summarize OBX news?
- Yes. Rallies summarizes OBX news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
- Is OBX research on Rallies investment advice?
- No. Rallies provides research, data, and educational context for OBX. It does not provide personalized investment advice.
